Braveheart Bio (NASDAQ:BRVE) Shares Gap Up – Time to Buy?

Shares of Braveheart Bio, Inc. (NASDAQ:BRVE) gapped up prior to trading on Monday. The stock had previously closed at $17.42, but opened at $19.08. Braveheart Bio shares last traded at $18.96, with a volume of 3,487 shares traded.

Analyst Ratings Changes

BRVE has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 target price on shares of Braveheart Bio in a research report on Tuesday, October 20th. Stifel Nicolaus assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They set a “buy” rating and a $45.00 target price for the company. Wall Street Zen upgraded Braveheart Bio to a “hold” rating in a report on Saturday, August 15th. The Goldman Sachs Group assumed coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Zacks Research upgraded Braveheart Bio to a “hold” rating in a report on Tuesday, September 1st. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Braveheart Bio presently has an average rating of “Moderate Buy” and a consensus target price of $45.25.

Braveheart Bio Stock Performance

The stock’s 50-day simple moving average is $22.72. The firm has a market capitalization of $1.79 billion and a price-to-earnings ratio of -7.81.

Braveheart Bio (NASDAQ:BRVE) last released its quarterly earnings data on Tuesday, September 8th. The company reported ($2.51) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($2.26). As a group, sell-side analysts expect that Braveheart Bio, Inc. will post -1.99 earnings per share for the current fiscal year.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.